Elsevier MDL releases major DiscoveryGate® upgrade to boost research productivity
SAN LEANDRO, CA - June 13, 2005 - Elsevier MDL is pleased to announce the release of an enhanced version of DiscoveryGate, the company's highly acclaimed content platform for chemistry and life sciences research. Leveraging MDL® Isentris® technology, the new DiscoveryGate provides improved performance and usability-helping researchers rapidly find critical scientific information from a broad array of sources.
"With more than 300 customers and thousands of users, DiscoveryGate is already a significant success in the global pharma and biotech R&D arenas," said Elsevier MDL CEO Lars Barfod. "Customer requirements for improved productivity played a key role in this major upgrade, which provides faster responses to complex queries, improved usability and easy installation and maintenance. DiscoveryGate continues to demonstrate the impressive enterprise-scale capabilities of the MDL Isentris development framework for science."
DiscoveryGate ( www.discoverygate.com) integrates information from 25 chemistry and pharmacology databases on a single hosted platform, providing direct links to the primary literature and integration with customers' internal systems.
For any given search, the platform provides comprehensive results in the context of the original query. For example, researchers querying specific reaction databases can use new "Also Found In" links to simultaneously retrieve related information from other chemistry, molecular biology, bioactivity, metabolism/toxicology, chemical sourcing and synthetic methodology databases.
The database links extend to important new sources including the xPharm® database, which is the world's largest pharmacological reference work, and MDL® Patent Chemistry Database, an extensive new reaction and factual database for scientists in chemistry and the life sciences.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information visit www.elsevier.com.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
Dr. Phil McHale
VP, Market and Corporate Communications
Phone: (510) 357-2222 ext. 3541
MDL, Isentris and DiscoveryGate are registered trademarks of MDL Information Systems, Inc. ('Elsevier MDL') in the United States and/or other countries. All rights reserved.